Literature DB >> 18201576

Viruses associated with human cancer.

Margaret E McLaughlin-Drubin1, Karl Munger.   

Abstract

It is estimated that viral infections contribute to 15-20% of all human cancers. As obligatory intracellular parasites, viruses encode proteins that reprogram host cellular signaling pathways that control proliferation, differentiation, cell death, genomic integrity, and recognition by the immune system. These cellular processes are governed by complex and redundant regulatory networks and are surveyed by sentinel mechanisms that ensure that aberrant cells are removed from the proliferative pool. Given that the genome size of a virus is highly restricted to ensure packaging within an infectious structure, viruses must target cellular regulatory nodes with limited redundancy and need to inactivate surveillance mechanisms that would normally recognize and extinguish such abnormal cells. In many cases, key proteins in these same regulatory networks are subject to mutation in non-virally associated diseases and cancers. Oncogenic viruses have thus served as important experimental models to identify and molecularly investigate such cellular networks. These include the discovery of oncogenes and tumor suppressors, identification of regulatory networks that are critical for maintenance of genomic integrity, and processes that govern immune surveillance.

Entities:  

Mesh:

Year:  2007        PMID: 18201576      PMCID: PMC2267909          DOI: 10.1016/j.bbadis.2007.12.005

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  389 in total

Review 1.  Activation of NF-kappaB by HTLV-I and implications for cell transformation.

Authors:  Shao-Cong Sun; Shoji Yamaoka
Journal:  Oncogene       Date:  2005-09-05       Impact factor: 9.867

Review 2.  Hepatitis B virus biology.

Authors:  C Seeger; W S Mason
Journal:  Microbiol Mol Biol Rev       Date:  2000-03       Impact factor: 11.056

Review 3.  Stealth and cunning: hepatitis B and hepatitis C viruses.

Authors:  Stefan F Wieland; Francis V Chisari
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

4.  Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals.

Authors:  R G Caldwell; J B Wilson; S J Anderson; R Longnecker
Journal:  Immunity       Date:  1998-09       Impact factor: 31.745

Review 5.  Understanding the hypercarcinogenic state in chronic hepatitis: a clue to the prevention of human hepatocellular carcinoma.

Authors:  Okio Hino; Kazunori Kajino; Tomoyuki Umeda; Yasuo Arakawa
Journal:  J Gastroenterol       Date:  2002       Impact factor: 7.527

6.  Integration of Friend murine leukemia virus into both alleles of the p53 oncogene in an erythroleukemic cell line.

Authors:  G G Hicks; M Mowat
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

Review 7.  The molecular genetics of cellular oncogenes.

Authors:  H E Varmus
Journal:  Annu Rev Genet       Date:  1984       Impact factor: 16.830

8.  Characterization of a highly divergent TT virus genome.

Authors:  R L Hallett; J P Clewley; F Bobet; P J McKiernan; C G Teo
Journal:  J Gen Virol       Date:  2000-09       Impact factor: 3.891

Review 9.  Pathogenesis of hepatitis C-associated hepatocellular carcinoma.

Authors:  T Jake Liang; Theo Heller
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

10.  The latency protein LANA2 from Kaposi's sarcoma-associated herpesvirus inhibits apoptosis induced by dsRNA-activated protein kinase but not RNase L activation.

Authors:  M Esteban; M A García; E Domingo-Gil; J Arroyo; C Nombela; C Rivas
Journal:  J Gen Virol       Date:  2003-06       Impact factor: 3.891

View more
  124 in total

1.  The role of the Epstein-Barr virus-encoded BARF1 gene expressed in human gastric epithelial cells.

Authors:  Shuying Li; Fang Zhang; Ji Li; Xuya Hu; Wei Zhao; Ke Zhang; Jintao Li
Journal:  Turk J Gastroenterol       Date:  2020-11       Impact factor: 1.852

Review 2.  Viral manipulation of DNA repair and cell cycle checkpoints.

Authors:  Mira S Chaurushiya; Matthew D Weitzman
Journal:  DNA Repair (Amst)       Date:  2009-05-26

Review 3.  Hepatitis viruses and non-Hodgkin's lymphoma: A review.

Authors:  Sibnarayan Datta; Soumya Chatterjee; Rudragoud S Policegoudra; Hemant K Gogoi; Lokendra Singh
Journal:  World J Virol       Date:  2012-12-12

4.  Major Histocompatibility Complex Class II HLA-DRα Is Downregulated by Kaposi's Sarcoma-Associated Herpesvirus-Encoded Lytic Transactivator RTA and MARCH8.

Authors:  Zhiguo Sun; Hem Chandra Jha; Yong-Gang Pei; Erle S Robertson
Journal:  J Virol       Date:  2016-08-26       Impact factor: 5.103

Review 5.  How virus persistence can initiate the tumorigenesis process.

Authors:  Simone Avanzi; Gualtiero Alvisi; Alessandro Ripalti
Journal:  World J Virol       Date:  2013-05-12

Review 6.  Molecular mechanisms of viral oncogenesis in humans.

Authors:  Nathan A Krump; Jianxin You
Journal:  Nat Rev Microbiol       Date:  2018-11       Impact factor: 60.633

Review 7.  The history of tumor virology.

Authors:  Ronald T Javier; Janet S Butel
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

8.  Human papillomavirus-16 E7 interacts with glutathione S-transferase P1 and enhances its role in cell survival.

Authors:  Anna M Mileo; Claudia Abbruzzese; Stefano Mattarocci; Emanuele Bellacchio; Paola Pisano; Antonio Federico; Vittoria Maresca; Mauro Picardo; Alessandra Giorgi; Bruno Maras; M Eugenia Schininà; Marco G Paggi
Journal:  PLoS One       Date:  2009-10-13       Impact factor: 3.240

9.  View and review on viral oncology research.

Authors:  Valeria Bergonzini; Cristiano Salata; Arianna Calistri; Cristina Parolin; Giorgio Palù
Journal:  Infect Agent Cancer       Date:  2010-05-24       Impact factor: 2.965

10.  Torque Teno Virus (TTV) distribution in healthy Russian population.

Authors:  Evgeny V Vasilyev; Dmitry Y Trofimov; Alexander G Tonevitsky; Valery V Ilinsky; Dmitriy O Korostin; Denis V Rebrikov
Journal:  Virol J       Date:  2009-09-07       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.